IFIH1 and interstitial lung disease: A systematic review by McPherson et al. (37) provides an overview of the management strategies adopted in anti-MDA5-positive clinically amyopathic DM-associated ILD, highlighting rituximab as a viable immunosuppressive option particularly in cases of refractory RP-ILD.